Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles L Bennett

Showing results (81-90 of 331) with videos related to

Pageof 34
Sort By:
Cancer Treatment and Research|February 21, 2008
Does reimbursement affect physicians' decision making? Examples from the use of recombinant erythropoietinJune M McKoy, Cara C Tigue, Charles L Bennett
Expert Opinion on Drug Safety|May 5, 2020
Response to: letter to the editor: consideration on 'an evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and drug administration and the European medicines agency' by bennett et alAndrew C Bennett, Charles L Bennett, Bartlett J Witherspoon
Seminars in Oncology|July 4, 2002
Cost-effectiveness considerations in the treatment of essential thrombocythemiaRobert Golub, Jared Adams, Sundeep Dave, et al.
Urology|November 19, 2013
Editorial commentSandip M Prasad, A Oliver Sartor, Charles L Bennett
JAMA Oncology|December 15, 2015
Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer TreatmentJordan D Lane, Mark W Friedberg, Charles L Bennett
Leukemia Research|April 1, 2016
Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registryJametta S Magwood-Golston, Samuel Kessler, Charles L Bennett
Drugs|November 18, 2018
Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to CompetitionBrian K Chen, Y Tony Yang, Charles L Bennett
Urology|January 28, 2015
Editorial commentTerhi Hermanson, Oliver Sartor, Richard Ablin, et al.
JAMA Oncology|February 17, 2017
Improving the Evidence Base for Delivery of High-Quality Cancer CareZaina P Qureshi, Patricia A Ganz, Charles L Bennett
Cancer Treatment and Research|December 15, 2007
The economics of brain metastasesCharles L Bennett, Cara C Tigue, Karen A Fitzner
Pageof 34

Showing results (81-90 of 331) with videos related to

Sort By:
Pageof 34
Cancer Treatment and Research|February 21, 2008
Does reimbursement affect physicians' decision making? Examples from the use of recombinant erythropoietinJune M McKoy, Cara C Tigue, Charles L Bennett
Expert Opinion on Drug Safety|May 5, 2020
Response to: letter to the editor: consideration on 'an evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and drug administration and the European medicines agency' by bennett et alAndrew C Bennett, Charles L Bennett, Bartlett J Witherspoon
Seminars in Oncology|July 4, 2002
Cost-effectiveness considerations in the treatment of essential thrombocythemiaRobert Golub, Jared Adams, Sundeep Dave, et al.
Urology|November 19, 2013
Editorial commentSandip M Prasad, A Oliver Sartor, Charles L Bennett
JAMA Oncology|December 15, 2015
Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer TreatmentJordan D Lane, Mark W Friedberg, Charles L Bennett
Leukemia Research|April 1, 2016
Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registryJametta S Magwood-Golston, Samuel Kessler, Charles L Bennett
Drugs|November 18, 2018
Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to CompetitionBrian K Chen, Y Tony Yang, Charles L Bennett
Urology|January 28, 2015
Editorial commentTerhi Hermanson, Oliver Sartor, Richard Ablin, et al.
JAMA Oncology|February 17, 2017
Improving the Evidence Base for Delivery of High-Quality Cancer CareZaina P Qureshi, Patricia A Ganz, Charles L Bennett
Cancer Treatment and Research|December 15, 2007
The economics of brain metastasesCharles L Bennett, Cara C Tigue, Karen A Fitzner
Pageof 34